secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001193125-24-258568
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aileron Therapeutics reports Q3 net loss of $5.8M; Phase 1b LTI-03 shows positive biomarker data
--------------------------------------------------------------------------------

- Net loss of $5.8M ($0.27 per share) compared to $1.8M ($0.40) in Q3 2023; R&D expenses increased to $3.7M from $0.1M.
- Cash and equivalents at $17.7M as of Sept 30, 2024, expected to fund operations into June 2025.
- Phase 1b high-dose LTI-03 (5mg BID) in IPF showed dose-dependent biomarker effects; combined cohort data achieved statistical significance in 4 of 8 biomarkers.
- Planning underway for Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis (IPF).
- Exclusive option agreement with Advancium Health Network for ALRN-6924 (oncology) granted; non-refundable fee received, potential milestone and royalty payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524258568/0001193125-24-258568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524258568/d912402d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-258568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer